logo
Share SHARE
FONT-SIZE Plus   Neg

Auxilium Pharma Reports Positive Top-line Data From XIAFLEX Phase IIIb Trial

Auxilium Pharmaceuticals Inc. (AUXL) reported positive top-line data from its open-label phase IIIb study, assessing XIAFLEX for the treatment of adult Dupuytren's contracture patients with multiple palpable cords. The company enrolled 60 patients at 8 sites throughout the U.S. and Australia. During the third quarter of 2012, Auxilium expects to begin a larger study with XIAFLEX for the concurrent treatment of multiple palpable cords that, if successful, may allow the company to seek Food and Drug Administration approval and expansion of the Dupuytren's label.

Based on research by SDI Health, LLC estimating that 35% - 40% of annual Dupuytren's surgeries in the U.S. are performed to treat two or more cords concurrently, Auxilium is conducting these trials to seek a multicord indication for XIAFLEX from the FDA.

In this phase IIIb multicord trial, 60 patients received two concurrent injections of 0.58 mg of XIAFLEX per affected hand and efficacy was based on a single injection per contracted joint.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
LinkedIn Corp. (LNKD) on Thursday posted a loss for the first-quarter that widened from a year ago, hurt largely by higher operating costs. On an adjusted basis, earnings for the quarter improved and trumped Wall Street estimates, as revenues jumped 35 percent led by growth across all segments. Shares... Daily deals site Groupon Inc. (GRPN) on Thursday reported a loss for the first quarter that widened from a year ago, hurt largely by lower revenues. Nevertheless, loss for the quarter were lower than what Wall Street expected, revenues also trumped estimates. Chicago, Illinois-based Groupon's first-quarter... Shares of Amazon.com Inc. (AMZN) jumped 12 percent in after-hours on Thursday after the online retailer reported a first-quarter profit and revenues that trumped Wall Street estimates. Seattle, Washington-based Amazon reported first-quarter profit of $513 million or $1.07 per share, compared with...
comments powered by Disqus
Follow RTT